Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy

Fig. 5

Potential mechanisms of the synergistic effect of chidamide combined with enzalutamide. A ConsensusCluster determined by ERGs in TS/A tumor samples. B The Sankey diagram displaying relationships among different treatment groups and gene clusters. C, D GSVA analysis of enriched pathways in cluster 2 compared with cluster 1 (C) and cluster 3 (D). E, F KEGG (E) and GO (F) analysis of differentially expressed genes among different treatment groups. G GSVA analysis of AR and steroid synthesis, and the P53 pathway among different treatment groups. H GSEA analysis of differentially expressed genes among different treatment groups. I Bar plots showing the percentage of CD3e+ cells among CD45+ cells, CD4+ cells among CD45+ T cells, CD8+ cells among CD45+ T cells, PRF1+ cells among CD3e+ CD45+ CD8+ T cells, CD206+ cells among CD45+ CD11b+ F4/80+ cells, and CD86+ cells among CD45+ CD11b+ F4/80+ cells. Data were compared using Student’s t test (I) or Mann–Whitney test (C–F)

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us